MedCap AB (publ) announces the final outcome in its recommended cash offer to the shareholders of AdderaCare
MedCap completes the recommended cash offer to the shareholders of AdderaCare and extends the acceptance period
MedCap AB (publ) announces a recommended cash offer at a price of SEK 3.60 per share to the shareholders of AdderaCare AB (publ)
THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SCHWEIZ, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED "IMPORTANT INFORMATION" AT THE END OF THIS ANNOUNCEMENT AND IN THE OFFER DOCUMENT WHICH WILL BE PUBLISHED SHORTLY PRIOR TO THE BEGINNING OF THE ACCEPTANCE PERIOD OF THE OFFER.
MedCap AB (publ) has, through its subsidiary Unimedic Pharma AB, signed an agreement to divest the rights to the product Vitamin D to Pharmaprim AB.